March 26 (Reuters) - Novo Nordisk:
* U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED AN UPDATE TO US PRESCRIBING INFORMATION FOR TRESIBA (INSULIN DEGLUDEC) TO INCLUDE DATA FROM THE DEVOTE TRIAL​
* ‍FOLLOWING INTERACTIONS WITH FDA, NOVO NORDISK HAS WITHDRAWN APPLICATIONS RELATED TO DATA FROM SWITCH TRIALS​
* ‍”VERY PLEASED THAT FDA HAS APPROVED UPDATED LABEL FOR TRESIBA AS ONLY BASAL INSULIN TO BE LABELLED WITH A LOWER RATE OF SEVERE HYPOGLYCAEMIA COMPARED TO INSULIN GLARGINE U100,” SAYS CSO MADS KROGSGAARD THOMSEN​ Source text for Eikon: Further company coverage: (Copenhagen newsroom)
